Dr. Brad Nelson, Director of the BC Cancer Agency’s Trev & Joyce Deeley Research Centre in Victoria, and his team lay the foundation for clinical trials involving a form of immunotherapy called “adoptive T cell therapy” or ACT. Groundbreaking cancer research has advanced from a concept to compelling scientific proof that enhancing the body’s natural immune response to cancer through ACT can have life-saving effects. $905,000 raised at the 2014 Jingle Mingle supports the construction of a clinical-grade T cell production suite, where scientists will culture patients’ T cells in a safe and sterile environment for clinical trials. Read More.